𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Single dose pharmacokinetics of HEPP, a new anticonvulsant in normal healthy volunteers

✍ Scribed by Dinora F. González-Esquivel; Francisco Rubio-Donnadieu; Guillermo Carvajal S.; Helgi Jung C.

Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
128 KB
Volume
19
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

✦ Synopsis

The pharmacokinetics and the dose proportionality of a new anticonvulsant compound, HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) was studied in healthy male volunteers as part of the pharmacological evaluation for new drugs. Study was performed administering doses of 250, 375, 500 and 625 mg of HEPP to six male volunteers. Blood and urine samples were collected for 72 h postdose and analysed by HPLC. Results showed that in man HEPP is rapidly absorbed from the gastrointestinal tract. T max values were between 1.5 and 6.0 h. Plasma mean terminal half-life after the different doses ranged between 15.83 and 27.62 h with an overall harmonic mean value of 22.8. The mean AUC 0-and C max increased linearly with doses of 250, 375 and 500 mg but not with the dose of 625 mg. The amount of unchanged drug excreted in urine was between 3 and 6% of administered dose which shows an extensive metabolism of the drug.

📜 SIMILAR VOLUMES

Single dose pharmacokinetics and bioavai
Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers
✍ Michael J. Lamson; John P. Sabo; Thomas R. Macgregor; Joseph W. Pav; Lois Rowlan 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 2 views

The results of two randomized, single-dose, crossover bioavailability studies are presented which describe the pharmacokinetics and oral bioavailability of nevirapine, a novel nonnucleoside antiretroviral drug. In the first study 12 healthy male volunteers received nevirapine 15 mg via short-term i.

The single dose pharmacokinetics and saf
The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers
✍ Harri Kanerva; Olavi Kilkku; Esa Heinonen; Antti Helminen; Juha Rouru; Simo Tarp 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 2 views

The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg

Dose-proportional pharmacokinetics of a
Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers
✍ Shekman L. Wong; Jeffrey Drajesk; Min S. Chang; Galen Witt; Walid M. Awni 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

, a new potent 5-lipoxygenase inhibitor, is under development for the treatment of asthma. The pharmacokinetics and dose proportionality of ABT-761 after single doses (10 -160 mg) of ABT-761 in 24 healthy male volunteers were investigated in a double-blind, placebo-controlled study. The compound was

Single-dose pharmacokinetics and anticon
Single-dose pharmacokinetics and anticonvulsant efficacy of primidone in mice
✍ Mr K. W. Leal; R. L. Rapport; A. J. Wilensky; P. N. Friel 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 374 KB

## Abstract The pharmacokinetics and efficacy of the anticonvulsant primidone (PRM) and its active metabolites, phenobarbital (PB) and phenylethylmalonamide (PEMA), were studied after single‐dose administration in mice. The half‐life of PB is twice that of PRM and PEMA. The plasma/brain ratios prov

Single- and multiple-dose pharmacokineti
Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2
✍ Dan C. Dimmitt; Youn Sung Choo; Lorene A. Martin; Thangam Arumugham; William F. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

The single-and multiple-dose pharmacokinetics and dose-proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was investigated in 18 healthy men. In an open-label, randomized, complete three-way crossover design, each subject received three separate doses: 50,

Dose proportionality and comparison of s
Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16 455) and its enantiomers in healthy male volunteers
✍ Doris K. Robbins; Mark A. Castles; David J. Pack; Vijay O. Bhargava; Scott J. We 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 2 views

The pharmacokinetics and dose proportionality of fexofenadine, a new non-sedating antihistamine, and its enantiomers were characterized after single and multiple-dose administration of its hydrochloride salt. A total of 24 healthy male volunteers (31 98 years) received oral doses of 20, 60, 120 and